Immune Checkpoint Inhibitors as Independent and Synergistic Drivers of SJS/TEN: A FAERS-Based Analysis

Eric Milan Mukherjee MD PhD[1, 2], Dodie Park[2], Matthew S. Krantz MD[2,3], Cosby A. Stone Jr. MD MPH[2,3], Michelle Martin-Pozo PhD[2,3], Elizabeth Phillips MD[2,3,4*]

[1]Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

[2]Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

[3]Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA

[4]Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Australia

*Corresponding author: elizabeth.j.phillips@vumc.org

Keywords: Severe Cutaneous Adverse Reactions, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Checkpoint Inhibitors, Pharmacovigilance, FAERS.

World Count: 3459

Key Points

Question: Do immune checkpoint inhibitors (ICIs) facilitate Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN), and do they synergize with known culprit drugs or impact disease latency?

Findings: In this cross-sectional study of 17,495 SJS/TEN cases from 13,986,839 deduplicated FAERS reports (2013–2023), ICI exposure, independent of exposure to known culprits, increased the risk of developing SJS/TEN and amplified risk when co-administered with known culprits such as allopurinol and trimethoprim-sulfamethoxazole. ICI-exposed patients also showed significantly delayed onset compared to non-exposed cases.

Meaning: These findings suggest that ICIs directly contribute to SJS/TEN, likely both as a direct cause and through mechanistic synergy with antigenic small molecule drugs. These findings underscore the need for heightened vigilance when combining ICIs with high-risk medications and for recognizing atypical, delayed presentations.

Abstract

Importance: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN) are rare, potentially fatal adverse drug reactions. As the use of immune checkpoint inhibitors (ICIs) expands, their role as direct inducers or synergistic contributors to SJS/TEN remains incompletely characterized.

Objective: To determine whether ICIs are independent risk factors for SJS/TEN, evaluate their interactions with known culprit drugs, and assess their impact on latency and mortality.

Design: Cross-sectional analysis of adverse event reports submitted to the U.S. Food and Drug Administration Adverse Event Reporting System (FDA FAERS) between January 2013 and December 2023, sanitized and de-duplicated. Logistic regression and Cox models were used to assess predictors of SJS/TEN development, mortality, and latency.

Setting: Global pharmacovigilance reports submitted to FAERS.

Participants: A total of 17,495 unique and de-identified patients reported SJS/TEN, of 13,986,839 total reports.

Exposures: Suspected causative drugs, including ICIs.

Main Outcomes and Measures: Primary outcomes were the adjusted odds of developing SJS/TEN, time-to-event (TTE) of reaction/drug latency, and all-cause mortality. Depending on the analysis, covariates included age, sex, number of concomitant drugs, cancer diagnosis, and specific drug exposures.

Results: Of 17,495 SJS/TEN cases (median age 53 years, 37.6% male), 970 (5.5%) had ICI exposure and 653 (3.7%) listed an ICI as the primary suspect. ICI exposure was associated with developing SJS/TEN (adjusted OR, 6.68; 95% CI, 6.18-7.22) while controlling for age, exposure to strong and weak culprits, number of concomitant drugs, and cancer diagnosis. ICI increases SJS-TEN risk among patients exposed to allopurinol (OR, 4.20; 95% CI, 3.02-5.86) and TMP-SMX (OR, 5.66; 95% CI, 4.04-7.93) with the same covariates. Among patients with small-molecule-induced SJS/TEN, mortality was strongly associated with ICI exposure (particularly exposure to multiple ICI, OR, 8.02; 95% CI, 3.44-18.73). Among all SJS/TEN cases, ICI exposure was associated with delayed onset, compared to cancer patients not exposed to ICI and non-cancer patients (median 20 vs 14 vs 13 days; P < .0001).

Conclusions and Relevance: ICIs are associated with increased SJS/TEN risk, both independently and in combination with known culprit drugs, and may delay disease onset. These findings support increased vigilance in prescribing known culprits alongside ICI.

Introduction

Immune checkpoint inhibitors (ICIs) are a novel class of antineoplastic drugs that have revolutionized treatment for many late-stage cancers.[1,2] However, because ICIs deactivate immune tolerance, they are associated with immune-related adverse events (irAE), of which cutaneous irAE are the most common.[3,4] Some of these reactions imitate Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), a rare blistering eruption most often triggered by small-molecule drugs like antibiotics, allopurinol, and antiepileptics.[5,6] Additionally, ICIs are the fastest-increasing drug class reported in association with SJS/TEN, reflecting both their expanding clinical use and a growing number of serious irAE captured in pharmacovigilance databases.[7]

There is also some controversy over the a distinction between "true" SJS/TEN to ICI and ICI-induced SJS/TEN-like reactions, which may be clinically and pathologically distinct from each other – the latter of which may represent a severe lichenoid or bullous reaction in some cases.[8–12] Additionally, ICIs may "prime" the risk of cutaneous irAE to known small-molecule culprits, though evidence for this is somewhat scarce. A retrospective study showed antibiotic use in patients receiving ICI increases the risk of some adverse events.[13] Another study suggested SJS/TEN-like reactions (referred to as progressive immunotherapy-related mucocutaneous eruption or PIRME in that publication) on ICI developed after exposure to a known culprit like allopurinol or trimethoprim-sulfamethoxazole (TMP-SMX), suggesting a two-hit mechanism in which ICIs create a permissive milieu for cutaneous adverse events to known culprit medications.[14,15]

To understand the interaction between ICI and small-molecule drugs in SJS/TEN, we present a comprehensive pharmacovigilance analysis of SJS/TEN using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) from 2013 to 2023. We assess the role of ICI and known culprit co-exposure on SJS/TEN risk, latency, and mortality. Using multivariable logistic regression, disproportionality analysis, and time-to-event (TTE) analysis, we investigate both the independent and interactive effects of ICI and small-molecule agents in SJS/TEN. Our findings aim to clarify the evolving landscape of drug-induced SJS/TEN and inform future mechanistic, clinical, and regulatory efforts.

Methods

All coding was done in RStudio 2024.12.0 Build 467 with R version 4.4.2, with GPT4o assistance. Figures were created using the gt (v0.11.1), ggplot2 (v3.5.1) and survminer (v0.5.0) packages, and GPT4o.

Data

A previously sanitized, deduplicated version of FAERS was used, pared to reports filed between January 2013 and December 2023.[7]

For combination drugs, TMP-SMX was considered the primary suspect if either TMP-SMX was directly coded as the primary suspect, if TMP was coded as the primary suspect and SMX was present on the drug list, or vice versa. For analyses of drug exposure, either TMP or SMX on the drug list was sufficient to consider the patient to be exposed to TMP-SMX. Combination drugs containing phenytoin or allopurinol were also included. Exposure to ICI was coded similarly. ICI exposure by group (PD-1, PD-L1, and CTLA-4) was also noted, and dual ICI exposure was coded by flagging patients exposed to more than one ICI. Biologics were distinguished from small molecules by flagging all drugs that contain a word ending in "mab" or "cept" using regex.

Cancer Diagnosis

FAERS' standard_case_indication table was used to flag cases with an associated cancer diagnosis using keywords. After this first pass, we found that 22422 ICI-exposed patients had no cancer diagnosis (11.8% of 189752 ICI-exposed patients). 14970 recorded uses of ICI used had "product used for unknown indication" as the indication and 10468 has no indication recorded. Subsequently, all drugs tied to a known cancer diagnosis were extracted and the top 1000 by frequency were manually annotated as exclusively used for cancer indications (e.g. checkpoint inhibitors, most kinase inhibitors except JAK inhibitors and those used for idiopathic pulmonary fibrosis) or not (e.g. rituximab, cyclophosphamide, and prednisone, which are commonly used for autoimmune disease). Exact keywords and drugs used can be found in the R markdown file in the online data.

Co-Exposure Disproportionality Analysis

To evaluate potential interactions between ICI (ipilimumab, nivolumab, pembrolizumab, atezolizumab, cemiplimab, avelumab, durvalumab tremelimumab, dostarlimab), and drugs known to cause SJS/TEN, we conducted a pairwise co-exposure analysis using reporting odds ratios (ROR). Based on literature, we selected a set of five strong culprits (lamotrigine, TMP-SMX, phenytoin, allopurinol, carbamazepine) and five weak culprits (azithromycin, ciprofloxacin, oxcarbazepine, sulfasalazine, and acyclovir). ICIs were grouped both collectively and by mechanistic subclass (PD-1, PD-L1, CTLA-4, and dual blockade). We conducted two complementary analyses, first evaluating

whether the addition of an ICI increased the OR of SJS/TEN in patients on a culprit medication, then evaluating whether the addition of a culprit medication increased the OR in patients receiving an ICI. Two-sided p-values were calculated using Fisher's exact test and corrected using the Benjamini-Hochberg procedure.

Logistic Regression

All logistic regressions for the risk of developing SJS/TEN and risk of mortality after developing SJS/TEN were conducted using the glm function in base R with the binomial model. Variance inflation factors (VIFs) for all variables in all models were < 5, suggesting no multicollinearity was detected (**eFigure 11**). For models with causative drug as a covariate, the top 10 drugs were included, and the rest coded as other (and used as the reference), due to technical limitations.

Time-to-Event Analysis

After removal of TTE outliers (<1 and >180 days), 4,086 cases had sufficient data for TTE analysis. Cox proportional hazards models were generated using R's survival package (v3.7-0).

Results

Demographics and ICI Exposure

We identified 17,495 unique SJS/TEN cases reported to FAERS between 2013 and 2023, of a total of 13,986,839 unique reports to FAERS (**Figure 1**). Median age was 53 years (IQR: 30–70), with slight female predominance (Female: 8591; Male: 6572; Not Specified: 2332). Most reports originated from Europe & Central Asia (6725), North America (5589), and East Asia & Pacific (3502). Mortality was 21.1% overall (3694 deaths). The most common primary suspects were lamotrigine (1545), ibuprofen (790), and allopurinol (736). Of ICI, pembrolizumab made the top 10 with 245 primary suspect cases. ICI exposure was recorded in 970 cases (5.5%), with 653 (3.7%) listing an ICI as the primary suspect. Pembrolizumab (245), nivolumab (225), and ipilimumab (72) were the most frequent primary suspects. By class, PD-1 inhibitors are the most implicated (847 exposed cases, of which 482 are primary suspects), though PD-L1 inhibitors have a higher proportion of implicated cases (118 exposed, 98 primary). Dual ICI regimens also have a high attribution rate (173 exposed, 146 with one of the ICI are coded as the primary suspect). CTLA-4 inhibitors have a lower attribution rate (182 exposed, 73 primary) than other classes.

Supplemental analyses comparing ICI-induced (meaning ICI marked as the primary suspect) and small-molecule-induced SJS/TEN cases revealed demographic distinctions (**eFigure 1**). ICI-induced cases skewed older and male, and were more often reported from East Asia and the Pacific, with less reporting from Europe and Central Asia.

ICI Exposure and the Development of, and Mortality Due to, SJS/TEN

We investigated disproportional reporting of SJS/TEN in patients receiving ICI and/or a set of predefined drugs, divided into strong (TMP-SMX, allopurinol, lamotrigine, phenytoin, and carbamazepine) and weak culprits (azithromycin, ciprofloxacin, oxcarbazepine, sulfasalazine, and acyclovir); this analysis was conducted in both directions (**Figure 2**). For patients on ICI, exposure to strong (OR = 4.7 [3.8-5.9], P < 0.001) or weak culprits (OR = 2.1 [1.4-3.1], P < 0.01) is disproportionately associated with SJS/TEN. Across patients exposed to any strong culprit, ICI co-exposure resulted in a modest increased odds of SJS-TEN (ROR, 1.7; 95% CI, 1.4-2.1, P < 0.001); patients exposed to a weak culprit had similar odds (ROR = 1.8 [1.23-2.6], P < 0.01). Particularly strong signals with dual ICI exposure were noted with patients on azithromycin (ROR = 18.9 [9.7-36.6], P < 0.001) and sulfasalazine (OR = 107 [23.2-493.5], P < 0.001), though limited by small sample sizes. In both directions, ORs are generally comparable or lower than ORs using the entire FAERS database as the background.

Of these culprits, the ones with the most frequent co-exposure in SJS/TEN patients are allopurinol (n = 43 cases) and TMP-SMX (44). In allopurinol-exposed patients, ICI increased the risk of SJS/TEN fourfold (OR = 4.20 [3.02-5.86]) after adjusting for age, sex, number of concomitant drugs, and cancer diagnosis using multivariate logistic regression (**eFigure 2**). Similar findings were observed for TMP-SMX (OR = 5.66 [4.04-7.93]) (**eFigure 3**). In both cases, cancer diagnosis was negatively associated with developing SJS/TEN (OR = 0.37 [0.32-0.42] for allopurinol, OR = 0.38 [0.32-0.45 for TMP-SMX), despite ICI being positively associated.

To evaluate risk factors for the development of SJS/TEN and mortality in SJS/TEN patients, we conducted two multivariable logistic regressions; the first included all reports, modeling SJS/TEN occurrence as the outcome., and the second was restricted to reports with documented SJS/TEN, modeling death as the outcome. Both models included age, sex, number of concomitant drugs, cancer diagnosis, ICI exposure, and exposure to strong or weak culprit drugs as covariates (**Figure 3**). In the development model, ICI exposure was associated with a markedly increased risk of SJS/TEN (OR = 6.68 [6.18-7.22]), as was strong culprit (OR = 14.02 [13.52-14.53]) and weak culprit exposure (OR = 2.56 [2.43-2.70]). Risk declined with increasing age, with ORs ranging from 0.64 for those

aged 21-40, to 0.40 for age 41-60, compared to age 0-20. Interestingly, cancer diagnosis was associated with lower risk (OR = 0.64 [0.61-0.67]). To determine whether drug exposures moderate this effect, we removed culprit and ICI exposure variables from the model, which increased the OR of cancer diagnosis to 1.10 [1.06-1.15]; this suggests some of the risk is mediated by drug exposure (**eFigure 4**).

In the mortality model, ICI exposure was independently associated with higher odds of death among SJS/TEN cases (OR = 1.19 [1.01-1.40]). Risk of death increased sharply with age, rising from an OR of 1.40 in patients aged 21-40 to 6.33 in those over 80. Cancer diagnosis was associated with increased mortality (OR = 1.80 [1.62-2.00]), in contrast to its inverse association with SJS/TEN development. Both strong and weak culprit exposure predicted increased mortality (OR = 1.15 [1.05-1.25] and 1.67 [1.49-1.88], respectively).

To further investigate predictors of SJS/TEN development and associated mortality, we conducted two additional multivariable logistic regressions, one with SJS/TEN as the outcome, limited to reports where a small molecule was listed as the primary suspect, and the other with death as the outcome, restricted to SJS/TEN cases with a small molecule as the primary suspect (**Figure 4**). Unlike the broader models, which evaluated exposure to pre-selected culprits, these models included the ten most common causative small molecules as covariates, with all other drugs grouped as the reference category. Additionally, ICI exposure was modeled with greater granularity using a three-level factor: no ICI exposure, exposure to a single ICI, and exposure to multiple ICIs. Other covariates included age, sex, and number of concomitant drugs.

In small-molecule-attributed cases, age was associated with lower SJS/TEN risk, with ages 41-60 (OR = 0.48 [0.46-0.51]) and 61-80 (OR = 0.50 [0.47-0.53]) having lower odds compared to age <20. Drugs *a priori* selected as strong culprits demonstrated strikingly increased SJS/TEN risk when listed as primary suspects, including allopurinol (OR = 92.64 [85.50-100.38]), lamotrigine (OR = 49.70 [46.99-52.56]), TMP-SMX (OR = 39.61 [34.66-45.28]), and phenytoin (OR = 30.66 [27.25-34.50]). Exposure to one (OR = 5.96 [5.25-6.76]) or multiple (OR = 4.87 [3.26-7.28]) ICI is independently associated with developing SJS/TEN. Mortality increases with age, with patients over 80 having an OR of 4.77 [3.90-5.82] relative to the youngest group. Some agents (e.g., acetaminophen, ibuprofen, TMP/SMX, lamotrigine) were associated with lower mortality despite elevated development risk. Allopurinol uniquely is associated with increased mortality (OR = 1.56 [1.33-1.84]). Importantly, ICI co-exposure is independently associated with mortality, with multiple ICI exposure (OR = 8.02 [3.44-18.73]) most strongly associated.

To assess confounding by indication, we performed additional regressions for SJS/TEN risk and mortality (as above) but restricted to cancer patients for whom a small molecule was the primary suspect of their adverse event (**eFigure 5**). Patterns were consistent with the general small-molecule-suspect population, including decreasing risk and increasing mortality with age. The most causative drugs, however, are quite different. While allopurinol (OR = 76.12 [58.04-99.83]) is strongly associated with the development of SJS/TEN in this population, there are also strong signals from antineoplastic agents of various classes, including the anti-hormonal apalutamide (OR = 12.61 [9.57-16.64], the alkylating agents bendamustine (OR = 8.46, [6.40-11.18]) and carboplatin (OR = 1.74, [1.41-2.15]), the antimetabolites methotrexate (OR = 4.61, [3.60-5.91]), and the kinase inhibitor vemurafenib (OR = 8.85 [6.92-11.32]). Like in the general population, allopurinol is associated with increased mortality risk (OR = 3.14 [1.85-5.34]), along with a handful of other agents. ICI exposure continued to strongly predict both SJS/TEN development (OR = 6.14 [5.33-7.06] for single-agent; OR = 5.74 [3.83-8.58] for multiple ICIs) and mortality (OR = 1.59 [1.17-2.16] and 4.28 [1.81-10.1], respectively).

We additionally conducted a regression for SJS/TEN risk on the population of patients for which ICI is the primary suspect, using age, sex, number of concomitant drugs, and co-exposure to strong and weak culprits as covariates (**eFigure 6**). Exposure to a strong culprit (allopurinol, lamotrigine, TMP-SMX, phenytoin, or carbamazepine) increased the odds of developing SJS/TEN (OR = 3.23 [2.28-4.58]). Among causative agents, pembrolizumab was most implicated and had a significantly elevated adjusted odds ratio (OR = 1.92 [1.47-2.52]) compared to the reference atezolizumab. We've also conducted another regression with the same variables, but grouping ICIs by class - CTLA-4, PD-1, PD-L1, and multiple classes with one marked as primary suspect (**eFigure 7**). Patients with multiple ICI had an increased odds ratio versus CTLA-4 (OR = 3.67 [2.08-6.50]). Exposure to a strong culprit is positively associated with developing SJS/TEN in this analysis as well (OR = 3.11 [2.20-4.41]).

The Effect of ICI on Drug Latency in SJS/TEN

We next analyzed TTE for all SJS/TEN cases with available latency information (n = 4,086, **Figure 5**). A Kaplan-Meier analysis shows that median latency is prolonged in patients exposed to ICI, compared to cancer patients not exposed to ICI and non-cancer patients (median, 20 vs 14 vs 13 days; log-rank P < .0001). In a Cox proportional hazards model, ICI exposure (HR = 0.77 [0.68–0.87], P < 0.001) and cancer diagnosis (HR = 0.76 [0.70-0.83], P < 0.001) was independently associated with delayed onset when controlling for sex, age, number of concomitant

drugs, and culprit exposure. Older patients showed modestly reduced hazard of earlier onset, with HR 0.69 [0.61-0.78] for patients aged 61-80, and HR 0.74 [0.64-0.86] for those >80 (both P < 0.001). This effect is even more pronounced in a latency analysis separating by the class of causative agent, ICI vs non-ICI biologic vs small-molecule (**eFigure 8**). Cases with ICI as a primary suspect of SJS/TEN had a median of 23.5 days latency, which is substantially increased compared to non-ICI biologics (15.0 days) and small molecule drugs (13.0 days, log-rank P < 0.0001). The corresponding Cox model including age, cancer diagnosis, causative drug class, number of concomitant drugs, and sex recapitulated this difference, with ICI having substantial delay (HR = 0.74 [0.65-0.85], P < 0.001) compared to small molecule drugs.

In a separate TTE analysis restricted to small-molecule-induced cases (n = 3,654, **eFigure 9**), ICI exposure was associated with delayed onset (median 15 vs 13 days, log-rank p < 0.0001). Latency varied by causative agent, with ibuprofen (HR = 2.58 [2.01–3.32]), TMP-SMX (HR = 2.36 [1.82–3.05]), and ciprofloxacin (HR = 2.20 [1.68-2.88]) linked to faster onset, and allopurinol (HR = 0.79 [0.66-0.94]), lamotrigine (HR = 0.77 [0.69-0.86]), lenalidomide (HR = 0.70 [0.55-0.87]), and phenytoin (HR = 0.69 [0.55-0.87]) associated with delayed onset. A separate analysis of small-molecule-induced SJS/TEN in cancer patients (n = 792, **eFigure 10**) recapitulates many of these findings, including delayed onset with age, but ICI exposure is significantly associated with onset (log-rank P = 0.033), though with decreased effect size (median 15 vs 14 days); when controlling for other variables in the corresponding Cox model, this effect became not significant (0.90 [0.70-1.115, P = 0.4). Capecitabine (HR = 4.50 [2.64-7.65]), regorafenib (HR = 2.24 [1.33-3.81]), and vemurafenib (HR = 1.53 [1.07-2.20]) are associated with faster onset. Lenvatinib (HR = 0.65 [0.42-1.02]) and lenalidomide (HR = 0.88 [0.68-1.14]) showed non-significant trends toward delayed onset.

Discussion

This study provides a comprehensive analysis of the effects of ICI exposure on SJS/TEN using a decade of pharmacovigilance data. Through multivariate regression, we find that ICI exposure is significantly associated with increased risk, delayed onset, and higher mortality in reported SJS/TEN. We also find that, in cases with ICI as primary suspect, exposure to known small-molecule culprits of SJS/TEN independently increases risk. This supports a two-hit mechanism in which ICI creates a permissive environment for the development of immune-mediated drug reactions.

Disproportionality analysis and multivariate models revealed that ICI exposure increased SJS/TEN risk and mortality after adjusting for covariates. Strong signals were observed for combinations involving TMP-SMX, lamotrigine, and allopurinol, which are well-documented in the literature.[5] The co-prescription of ICIs and sulfasalazine or azithromycin also showed striking risk elevations, though these were based on small counts and should be interpreted cautiously. Previous *in vitro* studies have found that checkpoint inhibition primes sulfamethoxazole- and sulfasalazine-specific T cells, corroborating these findings.[16,17] Similarly, ICI seems to potentiate vemurafenib-induced drug reaction with eosinophilia and systemic symptoms (DRESS), and a series of patients with lichenoid mucocutaneous reactions to ICI had 80% co-exposure to known causes of lichenoid drug eruptions.[18–21]

Multivariate models on the broader FAERS population revealed ICI exposure independently increased the risk of SJS/TEN even when known culprit drugs were controlled for, including when controlling for cancer diagnosis. Interestingly, cancer diagnosis was associated with reduced SJS/TEN risk in several models, including those focusing on patients exposed to TMP-SMX or allopurinol. However, when ICI and culprit exposure were removed, cancer diagnosis became weakly positively associated with SJS/TEN development, consistent with the literature.[22,23] The association may be specific for certain cancers or correlated with cancer severity, and in particular has been previously associated with hematologic malignancies.[22,24] These findings imply a nuanced relationship between malignancy and SJS/TEN, shaped by therapeutic context, pharmacologic triggers (antineoplastics, allopurinol for tumor lysis syndrome, or TMP/SMX for prophylaxis), and underlying disease, that requires well-phenotyped datasets for further analysis.

TTE analyses added a complementary dimension. In the general population, ICI exposure was associated with substantially delayed onset, even after adjusting for age, sex, drug exposures, and cancer diagnosis (which was also associated with delayed TTE, and this effect is even more stark when comparing patients for whom ICI is coded as the primary culprit. Consistent with this finding, previous literature has shown that ICI-induced reactions coded as SJS/TEN have delayed onset compared to small-molecule-induced SJS/TEN.[14] This effect was recapitulated when analyzing the effect of ICI exposure on TTE in small-molecule induced SJS-TEN, though it diminished when further subsetting to cancer patients, which is consistent with other TTE analyses showing that cancer diagnosis is associated with delayed onset. Additionally, several small-molecule drugs demonstrated latency consistent with prior

studies, including rapid onset with agents like TMP-SMX and ciprofloxacin, and delayed reactions with allopurinol, lamotrigine, and phenytoin.[7]

Our study has certain limitations. First, FAERS is subject to underreporting, duplicate entries, and reporting biases, particularly related to newer or high-profile drug classes like ICIs.[25,26] We attempted to mitigate these, but biases remain, and more advanced deduplication could improve these results.[27–29] Also, FAERS lacks comprehensive histories or laboratory confirmation of diagnosis; we thus cannot exclude misdiagnosis, incomplete drug or indication lists, and insufficient follow-up as a source of bias. In particular, ICI-induced SJS/TEN-like reactions can be clinically and pathologically distinct from small molecule SJS/TEN, and ICI-induced bullous or lichenoid reactions can imitate SJS/TEN; there is no distinction in FAERS between "true" SJS/TEN and SJS/TEN-like reactions, thus we assume they're reported together for the sake of this analysis.[8,30–33] Further studies should focus on well-phenotyped cohorts that can be distinguished clinically and histologically. Third, latency analyses rely on documentation of start dates, which can be inconsistent. Fourth, many ICI-culprit combinations had low counts, limiting generalizability, as there were no cases with ICI and carbamazepine or oxcarbazepine co-exposure. Studies of other databases, chart reviews, and prospective studies are needed to solidify the conclusions. Finally, we were unable to reliably code for cancer type and severity, so some findings may be partly mediated by the severity of the underlying condition or differences in the underlying biology of the neoplasm.

In aggregate, our findings highlight a pattern in which ICIs may act as both direct triggers of SJS/TEN, and facilitate reactions to small molecules, potentially by disrupting tolerance to drug antigens and lowering the threshold of T cell activation, leading to delayed-onset reactions resembling SJS/TEN.[16,17] These results reinforce the importance of monitoring in patients receiving ICI, particularly when prescribing high-risk medications. They also suggest that SJS/TEN risk stratification in oncology should not be limited to individual drug profiles but should additionally incorporate the immunologic milieu created by ICI in concert with the tumor microenvironment.

Data Sharing

Methods and data are available at https://github.com/capuhcheeno/SCARs_ICI-Manuscript-Scripts/tree/main/ICI%20and%20Culprit%20Analysis

Contributions

EMM conceived the project, wrote the manuscript, and conducted all statistical analyses. DP assisted with statistical analyses and edited the manuscript. MMP, MSK, and CAS assisted with analysis and reviewed the manuscript. EP reviewed all analyses and the manuscript.

Acknowledgements

E.J.P. is supported by the following grants from the National Institutes of Health (NIH): NIH U01AI154659, NIH P50GM115305, NIH R01HG010863, NIH R21AI139021, NIH R01AI152183, and NIH 2 D43 TW010559. E.J.P. is also supported by the National Health and Medical Research Council of Australia. E.M.M. is funded by a Vanderbilt University Medical Center internal career development award (Vanderbilt Faculty Research Scholars).

Conflict of Interest

E.J.P. receives royalties and consulting fees from UpToDate and UpToDate Lexidrug (where she is a Drug Allergy Section Editor and section author) and has received consulting fees from Janssen, Vertex, Verve, Servier, Rapt and Esperion. E.J.P. is co-director of IIID Pty Ltd, which holds a patent for HLA-B*57:01 testing for abacavir hypersensitivity, and E.J.P has a patent pending for detection of HLA-A*32:01 in connection with diagnosing drug reaction with eosinophilia and systemic symptoms to vancomycin. For these patents she does not receive any financial remuneration, and neither are related to the submitted work.

Statement on Use of Artificial Intelligence

GPT4o was used to write, optimize, and debug R, SQL and Python code. Suggestions were cross-referenced in literature, package documentation, and resources like stackoverflow.com. All code and generated data were manually reviewed, tested, and verified by the authors. The authors take responsibility for all code generated. GPT4o was also used for idea generation and assistance with clarity in manuscript writing.

Figure 1. Baseline Characteristics and ICI Involvement SJS/TEN Cases Reported to FAERS (2013-2023). (A) Distribution of ICI-associated SJS/TEN cases by drug and class. Bars indicate the number of cases where a given ICI was reported, with red segments denoting cases in which the ICI is the primary suspect. (B) Demographic, geographic, clinical, and drug exposure characteristics of SJS/TEN cases. IQR = interquartile range, F = female, M = male, NS = not specified.

Figure 2. Additive Effects of ICIs and Known Culprit Drugs on Reporting Risk of SJS/TEN. (A) Reporting odds ratios (RORs) for SJS/TEN among patients receiving an ICI (rows) as a reference population, in combination with an additional culprit (columns). (B) RORs for SJS/TEN among patients receiving a culprit (rows), as a reference population, in combination with an additional ICI (columns). In both panels, cells are shaded by the log-transformed ROR, and text shows the case count (n) and estimated ROR with 95% CI. *p < 0.05; **p < 0.01; ***p < 0.001.

	Level	N (Total)	N (SJS/TEN)	N (Deaths)	OR (Dev)	95% CI (Dev)	P (Dev)	OR (Mort)	95% CI (Mort)	P (Mort)
			Predictors of SJS/TEN Development and Mortality							
			Multivariate Logistic Regression on All FAERS Reports, 2013-2023							
Age (Years)	0-20 (ref)	580258	2226	196	1.00	-	-	1.00	-	-
	21-40	1199659	2696	312	0.64	[0.60–0.68]	<0.001	1.40	[1.16–1.70]	<0.001
	41-60	2460558	3389	651	0.40	[0.37–0.42]	<0.001	2.20	[1.85–2.61]	<0.001
	61-80	2984462	4522	1487	0.41	[0.39–0.43]	<0.001	4.28	[3.64–5.04]	<0.001
	80+	619937	1089	427	0.48	[0.45–0.52]	<0.001	6.33	[5.22–7.67]	<0.001
	Unknown	6141965	3573	621	0.14	[0.13–0.15]	<0.001	1.54	[1.27–1.88]	<0.001
Cancer Diagnosis	No (ref)	11698430	14357	2650	1.00	-	-	1.00	-	-
	Yes	2288409	3138	1044	0.64	[0.61–0.67]	<0.001	1.80	[1.62–2.00]	<0.001
Exposure to Strong Culprit	No (ref)	13645127	12255	2578	1.00	-	-	1.00	-	-
	Yes	341712	5240	1116	14.02	[13.52–14.53]	<0.001	1.15	[1.05–1.25]	0.00156
Exposure to Weak Culprit	No (ref)	13660142	15560	3123	1.00	-	-	1.00	-	-
	Yes	326697	1935	571	2.56	[2.43–2.70]	<0.001	1.67	[1.49–1.88]	<0.001
ICI Exposure	No (ref)	13797083	16525	3341	1.00	-	-	1.00	-	-
	Yes	189756	970	353	6.68	[6.18–7.22]	<0.001	1.19	[1.01–1.40]	0.0393
Number of Concomittant Drugs	Per Unit Increase	13986839	17495	3694	1.00	[1.00–1.00]	<0.001	1.01	[1.01–1.01]	<0.001
Sex	Female (ref)	7388660	8591	1685	1.00	-	-	1.00	-	-
	Male	4863436	6572	1501	1.01	[0.98–1.04]	0.502	1.13	[1.04–1.23]	0.00333
	Not Specified	1734743	2332	508	2.51	[2.38–2.65]	<0.001	1.75	[1.49–2.05]	<0.001

Figure 3. Predictors of SJS/TEN Development and Mortality. Multivariable logistic regression was used to assess factors associated with SJS/TEN case status (left columns) and death among SJS/TEN cases (right columns), using all reports in FAERS from 2013-2023 (n = 13,986,839). OR = odds ratio, CI = confidence interval, Dev = development, mort = mortality, ref = reference level.

Predictors of Small-Molecule-Induced SJS/TEN Development and Mortality

Multivariate Logistic Regression on FAERS, 2013-2023 (Restricted to Small Molecule Primary Suspects)

	Level	N (Total)	N (SJS/TEN)	N (Deaths)	OR (Dev)	95% CI (Dev)	P (Dev)	OR (Mort)	95% CI (Mort)	P (Mort)
Age (Years)	0-20 (ref)	490318	2199	192	1.00	-	-	1.00	-	-
	21-40	942045	2637	305	0.71	[0.67–0.75]	<0.001	1.22	[1.00–1.48]	0.0449
	41-60	1867299	3112	588	0.48	[0.46–0.51]	<0.001	1.84	[1.54–2.19]	<0.001
	61-80	2394548	3978	1292	0.50	[0.47–0.53]	<0.001	3.56	[3.01–4.21]	<0.001
	80+	540105	1045	407	0.57	[0.53–0.62]	<0.001	4.77	[3.90–5.82]	<0.001
	Unknown	4971142	3205	536	0.15	[0.14–0.16]	<0.001	1.26	[1.03–1.56]	0.0269
Causative Drug	Other (ref)	10221234	10358	2341	1.00	-	-	1.00	-	-
	acetaminophen	55313	517	54	8.28	[7.57–9.05]	<0.001	0.48	[0.36–0.65]	<0.001
	allopurinol	7244	736	278	92.64	[85.50–100.38]	<0.001	1.56	[1.33–1.84]	<0.001
	carbamazepine	12031	370	62	27.81	[25.00–30.93]	<0.001	0.94	[0.71–1.25]	0.662
	ciprofloxacin	26748	288	82	9.34	[8.30–10.51]	<0.001	1.18	[0.91–1.55]	0.215
	ibuprofen	60856	790	29	11.50	[10.68–12.37]	<0.001	0.20	[0.13–0.29]	<0.001
	lamotrigine	28547	1575	168	49.70	[46.99–52.56]	<0.001	0.61	[0.52–0.73]	<0.001
	levetiracetam	39436	293	52	6.07	[5.40–6.83]	<0.001	0.86	[0.62–1.18]	0.35
	No Primary Suspect Listed	741203	716	169	1.05	[0.97–1.13]	0.226	1.14	[0.95–1.37]	0.161
	phenytoin	8152	299	63	30.66	[27.25–34.50]	<0.001	1.18	[0.88–1.57]	0.264
	TMP / SMX	4693	234	22	39.61	[34.66–45.28]	<0.001	0.39	[0.25–0.62]	<0.001
ICI Exposure	Zero (ref)	11168712	15893	3208	1.00	-	-	1.00	-	-
	One	33393	258	96	5.96	[5.25–6.76]	<0.001	1.82	[1.40–2.36]	<0.001
	Multiple	3352	25	16	4.87	[3.26–7.28]	<0.001	8.02	[3.44–18.73]	<0.001
Number of Concomittant Drugs	Per Unit Increase	11205457	16176	3320	1.01	[1.01–1.01]	<0.001	1.01	[1.01–1.01]	<0.001
Sex	Female (ref)	5754366	8053	1563	1.00	-	-	1.00	-	-
	Male	4025318	5988	1305	1.02	[0.99–1.06]	0.178	1.11	[1.02–1.21]	0.0194
	Not Specified	1425773	2135	452	2.21	[2.09–2.33]	<0.001	1.83	[1.54–2.17]	<0.001

Figure 4. Predictors of Small-Molecule-Induced SJS/TEN Development and Mortality. Multivariable logistic regression was performed on all FAERS reports in which the primary suspect drug was a small molecule (n = 11,205,457), assessing factors associated with SJS/TEN (left columns) and death among SJS/TEN cases (right columns). Top 10 primary suspect drugs by frequency were modeled individually, with all others grouped as "Other". OR = odds ratio, CI = confidence interval, Dev = development, mort = mortality, ref = reference level.

Figure 5. Latency in SJS/TEN by Clinical Exposure. (A) Kaplan-Meier curves on all SJS/TEN cases in FAERS

with TTE information (n = 4,086) illustrate time to onset of SJS/TEN stratified by ICI exposure and cancer status.

Note that all ICI-exposed patients also have a cancer diagnosis. Patients exposed to ICIs (blue) had longer latency

compared to those with cancer but no ICI exposure (green) and those with neither cancer nor ICI exposure (red). P-

value by log-rank test. (B) A multivariable Cox proportional hazards model including age, sex, number of

concomitant drugs, cancer diagnosis, strong culprit exposure, and weak culprit exposure, identified ICI exposure as

a predictor of delayed SJS/TEN onset. IQR = interquartile range, CI = confidence interval, HR = hazard ratio, ref =

reference level.

eFigure 1. Demographic and Clinical Characteristics of ICI- vs Small-Molecule-Induced SJS/TEN.

Proportional distributions of (A) age, (B) sex, (C) reporting region, and (D) presence of strong culprits are shown for

SJS/TEN cases attributed to immune checkpoint inhibitors (ICI) versus small molecules (SM). F = female, M =

male, NS = not specified, PS = primary suspect.

SJS/TEN in Patients Exposed to Allopurinol

Multivariable Logistic Regression, FAERS 2013-2023

		N (Total)	N (SJS/TEN)	Odds Ratio	95% CI	P-value
Age (Years)	0-20 (ref)	1217	18	1.00	-	-
	21-40	2844	78	1.46	[0.86–2.48]	0.163
	41-60	17242	229	0.84	[0.51–1.37]	0.48
	61-80	54590	660	0.81	[0.50–1.31]	0.389
	80+	15911	261	0.87	[0.53–1.42]	0.576
	Unknown	29894	196	0.18	[0.11–0.29]	<0.001
Sex	Female (ref)	39798	618	1.00	-	-
	Male	71900	600	0.50	[0.44–0.56]	<0.001
	Not Specified	10000	224	4.24	[3.45–5.22]	<0.001
Number of Concomittant Drugs	Per Unit Increase	121698	1442	0.91	[0.90–0.92]	<0.001
ICI Exposure	No (ref)	119361	1399	1.00	-	-
	Yes	2337	43	4.20	[3.02–5.86]	<0.001
Cancer Diagnosis	No (ref)	69898	1168	1.00	-	-
	Yes	51800	274	0.37	[0.32–0.42]	<0.001

eFigure 2. Risk Factors for SJS/TEN Among Patients Exposed to Allopurinol. Multivariable logistic regression was performed among 121,698 allopurinol-exposed cases reported to FAERS from 2013-2023 to identify demographic and clinical factors associated with SJS/TEN. OR = odds ratio, CI = confidence interval, ref = reference level.

SJS/TEN in Patients Exposed to TMP-SMX

Multivariable Logistic Regression, FAERS 2013-2023

		N (Total)	N (SJS/TEN)	Odds Ratio	95% CI	P-value
Age (Years)	0-20 (ref)	7969	91	1.00	-	-
	21-40	7976	141	1.19	[0.91–1.55]	0.209
	41-60	19503	255	1.04	[0.82–1.33]	0.731
	61-80	26872	236	0.77	[0.60–0.98]	0.0328
	80+	4386	94	1.69	[1.27–2.27]	<0.001
	Unknown	23576	143	0.36	[0.27–0.49]	<0.001
Sex	Female (ref)	41458	481	1.00	-	-
	Male	38653	374	0.87	[0.76–1.00]	0.0431
	Not Specified	10171	105	1.88	[1.44–2.45]	<0.001
Number of Concomittant Drugs	Per Unit Increase	90282	960	0.99	[0.98–0.99]	<0.001
ICI Exposure	No (ref)	88713	916	1.00	-	-
	Yes	1569	44	5.66	[4.04–7.93]	<0.001
Cancer Diagnosis	No (ref)	53536	745	1.00	-	-
	Yes	36746	215	0.38	[0.32–0.45]	<0.001

eFigure 3. Risk Factors for SJS/TEN Among Patients Exposed to TMP-SMX. Multivariable logistic regression was performed among 90,282 TMP-SMX-exposed cases reported to FAERS from 2013-2023 to identify demographic and clinical factors associated with SJS/TEN. OR = odds ratio, CI = confidence interval, ref = reference level.

Predictors of SJS/TEN Development and Mortality in FAERS

Multivariate Logistic Regression on All FAERS Reports, 2013–2023

	Level	N (Total)	N (SJS/TEN)	N (Deaths)	OR (Dev)	95% CI (Dev)	P (Dev)	OR (Mort)	95% CI (Mort)	P (Mort)
Age (Years)	0-20 (ref)	580258	2226	196	1.00	-	-	1.00	-	-
	21-40	1199659	2696	312	0.62	[0.58–0.65]	<0.001	1.37	[1.13–1.65]	0.00121
	41-60	2460558	3389	651	0.37	[0.35–0.39]	<0.001	2.14	[1.80–2.54]	<0.001
	61-80	2984462	4522	1487	0.40	[0.38–0.42]	<0.001	4.15	[3.53–4.87]	<0.001
	80+	619937	1089	427	0.46	[0.43–0.50]	<0.001	6.17	[5.09–7.47]	<0.001
	Unknown	6141965	3573	621	0.12	[0.11–0.12]	<0.001	1.46	[1.20–1.78]	<0.001
Cancer Diagnosis	No (ref)	11698430	14357	2650	1.00	-	-	1.00	-	-
	Yes	2288409	3138	1044	1.10	[1.06–1.15]	<0.001	1.81	[1.66–1.98]	<0.001
Number of Concomitant Drugs	Per Unit Increase	13986839	17495	3694	1.01	[1.01–1.01]	<0.001	1.01	[1.01–1.01]	<0.001
Sex	Female (ref)	7388660	8591	1685	1.00	-	-	1.00	-	-
	Male	4863436	6572	1501	1.13	[1.09–1.17]	<0.001	1.14	[1.05–1.24]	0.00169
	Not Specified	1734743	2332	508	2.63	[2.50–2.77]	<0.001	1.77	[1.52–2.07]	<0.001

eFigure 4. Predictors of SJS/TEN Development and Mortality, with Fewer Covariates. Multivariable logistic regression was used to assess factors associated with SJS/TEN case status (left columns) and death among SJS/TEN cases (right columns), using all reports in FAERS from 2013-2023 (n = 13,986,839). OR = odds ratio, CI = confidence interval, Dev = development, mort = mortality, ref = reference level.

Predictors of Small-Molecule-Induced SJS/TEN Development and Mortality (Cancer Patients)

Multivariate Logistic Regression on FAERS, 2013-2023 (Restricted to Small Molecule Primary Suspects With Cancer Diagnosis)

	Level	N (Total)	N (SJS/TEN)	N (Deaths)	OR (Dev)	95% CI (Dev)	P (Dev)	OR (Mort)	95% CI (Mort)	P (Mort)
Age (Years)	0-20 (ref)	49590	110	53	1.00	-	-	1.00	-	-
	21-40	63390	127	46	1.00	[0.77–1.30]	0.983	0.76	[0.44–1.32]	0.327
	41-60	308459	480	124	0.81	[0.65–1.01]	0.0635	0.53	[0.32–0.86]	0.0109
	61-80	643573	912	317	0.76	[0.62–0.95]	0.0139	0.82	[0.52–1.31]	0.409
	80+	127518	98	41	0.46	[0.35–0.62]	<0.001	1.05	[0.57–1.95]	0.866
	Unknown	748455	458	121	0.30	[0.24–0.38]	<0.001	0.52	[0.31–0.88]	0.0142
Causative Drug	Other (ref)	1484468	1451	439	1.00	-	-	1.00	-	-
	allopurinol	731	62	36	76.12	[58.04–99.83]	<0.001	3.14	[1.85–5.34]	<0.001
	apalutamide	6662	55	31	12.61	[9.57–16.64]	<0.001	3.18	[1.78–5.70]	<0.001
	bendamustine	6387	52	18	8.46	[6.40–11.18]	<0.001	1.52	[0.84–2.76]	0.165
	capecitabine	43059	49	21	1.21	[0.91–1.62]	0.182	2.29	[1.27–4.12]	0.00578
	carboplatin	30051	102	28	1.74	[1.41–2.15]	<0.001	0.70	[0.43–1.13]	0.146
	lenalidomide	292087	159	31	0.69	[0.59–0.82]	<0.001	0.59	[0.39–0.90]	0.0139
	methotrexate	13727	76	45	4.61	[3.60–5.91]	<0.001	3.29	[1.91–5.68]	<0.001
	No Primary Suspect Listed	30752	69	32	1.91	[1.49–2.43]	<0.001	1.70	[1.03–2.83]	0.0388
	paclitaxel	25076	42	11	1.12	[0.82–1.53]	0.466	0.92	[0.45–1.86]	0.806
	vemurafenib	7985	68	10	8.85	[6.92–11.32]	<0.001	0.56	[0.28–1.12]	0.1
ICI Exposure	Zero (ref)	1904240	1902	590	1.00	-	-	1.00	-	-
	One	33393	258	96	6.14	[5.33–7.06]	<0.001	1.59	[1.17–2.16]	0.00289
	Multiple	3352	25	16	5.74	[3.83–8.58]	<0.001	4.28	[1.81–10.11]	<0.001
Number of Concomittant Drugs	Per Unit Increase	1940985	2185	702	1.00	[1.00–1.00]	<0.001	1.04	[1.03–1.05]	<0.001
Sex	Female (ref)	858637	1038	305	1.00	-	-	1.00	-	-
	Male	852523	890	315	0.80	[0.73–0.88]	<0.001	1.23	[1.00–1.51]	0.0484
	Not Specified	229825	257	82	1.64	[1.40–1.92]	<0.001	1.55	[1.07–2.26]	0.0207

eFigure 5. Predictors of Small-Molecule-Induced SJS/TEN Development and Mortality in Cancer Patients.
Multivariable logistic regression was performed on 1,940,985 reports in FAERS from 2013-2023, restricted to cases with a cancer diagnosis and a small-molecule primary suspect drug. Odds ratios are shown for both SJS/TEN development (left columns) and mortality among SJS/TEN cases (right columns). OR = odds ratio, CI = confidence interval, Dev = development, mort = mortality, ref = reference level.

Predictors of ICI-Induced SJS/TEN Development and Mortality

Multivariate Logistic Regression on FAERS, 2013–2023 (Restricted to ICI Primary Suspects)

	Level	N (Total)	N (SJS/TEN)	N (Deaths)	OR (Dev)	95% CI (Dev)	P (Dev)	OR (Mort)	95% CI (Mort)	P (Mort)
Age (Years)	Unknown (ref)	44979	152	42	1.00	-	-	1.00	-	-
	0-20	500	0	-	0.00	[0.00-2.07e+143]	0.946	-	-	-
	21-40	4487	15	4	1.20	[0.70-2.07]	0.512	1.29	[0.36-4.68]	0.698
	41-60	28002	142	41	1.87	[1.45-2.43]	<0.001	1.38	[0.72-2.67]	0.334
	61-80	62592	322	127	1.87	[1.49-2.35]	<0.001	2.32	[1.28-4.19]	0.00542
	80+	7392	22	10	1.03	[0.65-1.64]	0.887	2.44	[0.88-6.80]	0.088
Causative Drug	atezolizumab (ref)	19033	74	18	1.00	-	-	1.00	-	-
	avelumab	1852	1	1	0.15	[0.02-1.11]	0.0628	7.12e+06	[0.00]	0.986
	cemiplimab	1560	11	6	1.84	[0.96-3.53]	0.0666	4.84	[1.26-18.51]	0.0213
	dostarlimab	397	1	0	0.66	[0.09-4.78]	0.681	0.00	[0.00]	0.988
	durvalumab	8730	23	3	0.73	[0.45-1.16]	0.18	0.39	[0.09-1.57]	0.184
	ipilimumab	14978	72	19	1.37	[0.98-1.90]	0.063	1.30	[0.60-2.82]	0.501
	nivolumab	61655	225	68	1.04	[0.80-1.36]	0.762	1.65	[0.88-3.09]	0.121
	pembrolizumab	39655	245	109	1.92	[1.47-2.52]	<0.001	3.21	[1.72-5.99]	<0.001
	tremelimumab	92	1	0	2.96	[0.41-21.59]	0.284	0.00	[0.00]	0.988
Exposure to Strong Culprit	No (ref)	145307	613	208	1.00	-	-	1.00	-	-
	Yes	2645	40	16	3.23	[2.28-4.58]	<0.001	1.15	[0.56-2.33]	0.703
Exposure to Weak Culprit	No (ref)	146567	642	219	1.00	-	-	1.00	-	-
	Yes	1385	11	5	1.22	[0.65-2.29]	0.532	1.40	[0.40-4.95]	0.602
Number of Concomittant Drugs	Per Unit Increase	147952	653	224	1.01	[1.00-1.03]	0.0203	1.04	[1.01-1.07]	0.0173
Sex	Female (ref)	50031	222	77	1.00	-	-	1.00	-	-
	Male	80169	340	118	0.95	[0.80-1.13]	0.572	1.00	[0.69-1.46]	0.982
	Not Specified	17752	91	29	1.93	[1.45-2.57]	<0.001	2.29	[1.10-4.78]	0.0272

eFigure 6. Predictors of ICI-Induced SJS/TEN Development and Mortality, Stratified by Individual ICI.

Multivariable logistic regression was performed on 147,952 FAERS reports from 2013-2023, restricted to cases where an ICI was the primary suspect of their adverse reaction. Atezolizumab served as the reference drug. OR = odds ratio, CI = confidence interval, Dev = development, mort = mortality, ref = reference level.

Predictors of ICI-Induced SJS/TEN Development and Mortality

Multivariate Logistic Regression on FAERS, 2013–2023 (Restricted to ICI Primary Suspects, Grouped by Class)

	Level	N (Total)	N (SJS/TEN)	N (Deaths)	OR (Dev)	95% CI (Dev)	P (Dev)	OR (Mort)	95% CI (Mort)	P (Mort)
Age (Years)	Unknown (ref)	44979	152	42	1.00	-	-	1.00	-	-
	0-20	500	0	-	0.00	[0.00-5.46e+143]	0.946	-	-	-
	21-40	4487	15	4	1.12	[0.65-1.94]	0.675	1.37	[0.38-4.96]	0.628
	41-60	28002	142	41	1.76	[1.35-2.28]	<0.001	1.29	[0.67-2.47]	0.45
	61-80	62592	322	127	1.78	[1.41-2.24]	<0.001	2.21	[1.23-3.97]	0.00787
	80+	7392	22	10	1.03	[0.65-1.63]	0.914	2.60	[0.95-7.16]	0.0636
Causative ICI Class	CTLA-4 (ref)	8519	13	6	1.00	-	-	1.00	-	-
	PD-L1	28205	83	20	1.71	[0.95-3.08]	0.0735	0.25	[0.07-0.88]	0.031
	PD-1	87940	411	158	3.00	[1.73-5.22]	<0.001	0.62	[0.19-1.96]	0.413
	Multiple	23288	146	40	3.67	[2.08-6.50]	<0.001	0.35	[0.11-1.13]	0.0787
Exposure to Strong Culprit	No (ref)	145307	613	208	1.00	-	-	1.00	-	-
	Yes	2645	40	16	3.11	[2.20-4.41]	<0.001	1.12	[0.56-2.24]	0.751
Exposure to Weak Culprit	No (ref)	146567	642	219	1.00	-	-	1.00	-	-
	Yes	1385	11	5	1.25	[0.67-2.33]	0.49	1.51	[0.43-5.32]	0.525
Number of Concomittant Drugs	Per Unit Increase	147952	653	224	1.01	[1.00-1.02]	0.0973	1.04	[1.00-1.07]	0.0263
Sex	Female (ref)	50031	222	77	1.00	-	-	1.00	-	-
	Male	80169	340	118	0.90	[0.76-1.07]	0.237	0.99	[0.68-1.43]	0.944
	Not Specified	17752	91	29	1.76	[1.32-2.33]	<0.001	1.77	[0.86-3.61]	0.119

eFigure 7. Predictors of ICI-Induced SJS/TEN Development and Mortality, Grouped by ICI Class.

Multivariable logistic regression was performed on 147,952 FAERS reports from 2013-2023, restricted to cases where an ICI was the primary suspect of their adverse reaction. Primary suspects were categorized into CTLA-4, PD-L1, PD-1, or multiple ICI classes. OR = odds ratio, CI = confidence interval, Dev = development, mort = mortality, ref = reference level.

A Time to Onset in SJS/TEN by Causative Drug Class

Causative Drug	Median [IQR], days	Mean [95%% CI], days
Small Molecule	13.0 [6.0–25.0]	19.7 [19.0–20.5]
Non-ICI Biologic	15.0 [8.0–31.5]	31.1 [25.3–37.0]
ICI	23.5 [11.0–46.0]	34.9 [30.7–39.1]

Number at risk

Causative Drug Group										
Small Molecule	3654	1219	407	196	118	64	43	27	13	1	0
Non-ICI Biologic	166	63	36	29	21	13	11	7	1	0	0
ICI	266	150	84	45	31	21	13	6	1	0	0

B

Latency Model - SJS/TEN By Causative Drug Class
Cox Proportional Hazards Model for Time-to-Onset of SJS/TEN

	Level	N	HR	95% CI	P
Age (Years)	0-20 (ref)	323	1.00	-	-
	21-40	564	0.77	[0.67-0.88]	<0.001
	41-60	985	0.75	[0.66-0.85]	<0.001
	61-80	1473	0.71	[0.62-0.80]	<0.001
	80+	418	0.76	[0.66-0.88]	<0.001
	Unknown	323	0.78	[0.63-0.98]	0.0323
Cancer Diagnosis	No (ref)	2919	1.00	-	-
	Yes	1167	0.78	[0.72-0.85]	<0.001
Causative Drug Class	Small Molecule (ref)	3654	1.00	-	-
	Non-ICI Biologic	166	0.78	[0.66-0.91]	0.00202
	ICI	266	0.74	[0.65-0.85]	<0.001
Number of Concomitant Drugs	Per Unit Increase	-	1.00	[1.00-1.00]	0.843
Sex	Female (ref)	2086	1.00	-	-
	Male	1753	1.00	[0.93-1.06]	0.905
	Not Specified	247	0.89	[0.71-1.11]	0.301

eFigure 8. Latency of SJS/TEN by Causative Drug Class. (A) Kaplan-Meier curves comparing time-to-onset of SJS/TEN across three drug groups (n = 4,086): small molecules (red), non-ICI biologics (green), and ICIs (blue). ICIs were associated with significantly longer latency compared to the other groups (log-rank $p < 0.0001$). (B) Cox proportional hazards model adjusted for age, sex, cancer diagnosis, and number of concomitant drugs confirms that ICI and non-ICI biologics have significantly reduced hazard of early SJS/TEN onset compared to small molecules. IQR = interquartile range, CI = confidence interval, HR = hazard ratio, ref = reference level.

eFigure 9. Latency of Small-Molecule-Induced SJS/TEN. (A) Kaplan-Meier curves comparing time-to-onset across two groups with small-molecule-induced SJS/TEN (n = 3,654): ICI exposed (red) and non-ICI exposed (green). ICI exposure was associated with significantly longer latency (log-rank P = < 0.0001). (B) Cox proportional hazards model adjusted for age, sex, causative drug, and number of concomitant drugs confirms that ICI exposure significantly reduces hazard of early SJS/TEN (HR = 0.67, [0.55-0.82]). IQR = interquartile range, CI = confidence interval, HR = hazard ratio, ref = reference level.

eFigure 10. Latency of Small-Molecule-Induced SJS/TEN in Cancer Patients. (A) Kaplan-Meier curves comparing time-to-onset across two groups with small-molecule-induced SJS/TEN and cancer (n = 792): ICI exposed (red) and non-ICI exposed (green). ICI exposure was associated with significantly longer latency (log-rank P = 0.033). (B) Cox proportional hazards model adjusted for age, sex, causative drug, number of concomitant drugs, and ICI exposure. IQR = interquartile range, CI = confidence interval, HR = hazard ratio, ref = reference level.

eFigure 11. Generalized Variance Inflation Factor (GVIF) Heatmap Across Regression Models. GVIF values are shown for each predictor across multiple regression models assessing SCAR development and mortality. While some models approach a GVIF of 2 for age and sex, all values remain below the conventional multicollinearity concern threshold of 5, indicating acceptable collinearity. Color intensity reflects the degree of GVIF inflation, with darker shades indicating higher values.

References

1. Topalian SL, Hodi FS, Brahmer JR, et al. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. *JAMA Oncol*. 2019;5(10):1411-1420. doi:10.1001/jamaoncol.2019.2187

2. Alexander W. The Checkpoint Immunotherapy Revolution. *P T*. 2016;41(3):185-191.

3. Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. *Am J Clin Dermatol*. 2018;19(3):345-361. doi:10.1007/s40257-017-0336-3

4. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. *Cancer Discovery*. 2018;8(9):1069-1086. doi:10.1158/2159-8290.CD-18-0367

5. Lee EY, Knox C, Phillips EJ. Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. *JAMA Dermatol*. 2023;159(4):384-392. doi:10.1001/jamadermatol.2022.6378

6. Hung SI, Mockenhaupt M, Blumenthal KG, et al. Severe cutaneous adverse reactions. *Nat Rev Dis Primers*. 2024;10(1):30. doi:10.1038/s41572-024-00514-0

7. Mukherjee EM, Park D, Krantz MS, Stone CA, Martin-Pozo M, Phillips E. Demographics, Latency, and Mortality of Severe Cutaneous Adverse Reactions in an FDA Database. Published online May 16, 2025:2025.03.05.25323441. doi:10.1101/2025.03.05.25323441

8. Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series. *J Am Acad Dermatol*. 2020;83(5):1475-1477. doi:10.1016/j.jaad.2020.03.029

9. Hill J, Ravi M, Korman AM, Dulmage B, Kaffenberger BH. Characterizing immune checkpoint inhibitor-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: Caution Advised. *J Am Acad Dermatol*. Published online May 30, 2025:S0190-9622(25)02217-0. doi:10.1016/j.jaad.2025.03.103

10. Zheng Z, Shen Z. Clinical characteristics of Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions induced by immune checkpoint inhibitors. *Oncologist*. 2025;30(6):oyaf143. doi:10.1093/oncolo/oyaf143

11. Li R, Lei H, Wang C, Liu X. Clinical features of nivolumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis based on case reports. *Front Immunol*. 2025;16:1563100. doi:10.3389/fimmu.2025.1563100

12. Kuo AM, Markova A. High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer. *Front Med (Lausanne)*. 2022;9:898790. doi:10.3389/fmed.2022.898790

13. Jing Y, Chen X, Li K, et al. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. *J Immunother Cancer*. 2022;10(1):e003779. doi:10.1136/jitc-2021-003779

14. Molina GE, Yu Z, Foreman RK, Reynolds KL, Chen ST. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series. *Journal of the American Academy of Dermatology*. 2020;83(5):1475-1477. doi:10.1016/j.jaad.2020.03.029

15. Molina GE, Otto TS, Yu Z, Foreman RK, Reynolds KL, Chen ST. Response to: "Immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis-like reactions." *Journal of the American Academy of Dermatology*. 2021;85(2):e111-e112. doi:10.1016/j.jaad.2021.04.028

16. Grice S, Saide K, Farrell L, et al. Immune checkpoint blockade lowers the threshold of naïve T-cell priming to drug-associated antigens in a dose-dependent fashion. *Toxicol Sci*. 2024;202(1):13-18. doi:10.1093/toxsci/kfae118

17. Hammond S, Olsson-Brown A, Grice S, et al. Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. *Toxicological Sciences*. 2022;186(1):58-69. doi:10.1093/toxsci/kfab144

18. Rana J, Maloney NJ, Rieger KE, et al. Drug-induced hypersensitivity syndrome like reaction with angioedema and hypotension associated with BRAF inhibitor use and antecedent immune checkpoint therapy. *JAAD Case Reports*. 2021;13:147-151. doi:10.1016/j.jdcr.2021.04.033

19. Maloney NJ, Rana J, Yang JJ, Zaba LC, Kwong BY. Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review. *Support Care Cancer*. 2022;30(3):2839-2851. doi:10.1007/s00520-021-06543-9

20. Naqash AR, File DM, Ziemer CM, et al. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. *J Immunother Cancer*. 2019;7(1):4. doi:10.1186/s40425-018-0475-y

21. Shi VJ, Rodic N, Gettinger S, et al. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. *JAMA Dermatol*. 2016;152(10):1128-1136. doi:10.1001/jamadermatol.2016.2226

22. Frey N, Jossi J, Bodmer M, et al. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. *Journal of Investigative Dermatology*. 2017;137(6):1240-1247. doi:10.1016/j.jid.2017.01.031

23. Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL. Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort. *Journal of Investigative Dermatology*. 2017;137(9):2021-2023. doi:10.1016/j.jid.2017.05.010

24. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. *Journal of Investigative Dermatology*. 2016;136(7):1387-1397. doi:10.1016/j.jid.2016.03.023

25. Neha R, Subeesh V, Beulah E, Gouri N, Maheswari E. Existence of Notoriety Bias in FDA Adverse Event Reporting System Database and Its Impact on Signal Strength. *Hosp Pharm*. 2021;56(3):152-158. doi:10.1177/0018578719882323

26. Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). *Expert Opin Drug Saf*. 2017;16(7):761-767. doi:10.1080/14740338.2017.1323867

27. Artificial Intelligence-based Deduplication Algoirthm for Classfication of Duplicate Reports in the FDA Adverse Event Reports (FAERS) | ACT-IAC. Accessed May 7, 2025. https://www.actiac.org/et-use-case/artificial-intelligence-based-deduplication-algoirthm-classfication-duplicate-reports

28. Kreimeyer K, Spiker J, Dang O, De S, Ball R, Botsis T. Deduplicating the FDA adverse event reporting system with a novel application of network-based grouping. *J Biomed Inform*. 2025;165:104824. doi:10.1016/j.jbi.2025.104824

29. Kreimeyer K, Dang O, Spiker J, et al. Increased Confidence in Deduplication of Drug Safety Reports with Natural Language Processing of Narratives at the US Food and Drug Administration. *Front Drug Saf Regul*. 2022;2. doi:10.3389/fdsfr.2022.918897

30. Bray ER, Lin RR, Li JN, Elgart GW, Elman SA, Maderal AD. Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases. *Arch Dermatol Res*. 2024;316(6):233. doi:10.1007/s00403-024-03061-6

31. Chen CB, Hung SI, Chang JWC, et al. Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade. *Nat Commun*. 2024;15(1):10733. doi:10.1038/s41467-024-54180-7

32. Mattson G, Gutierrez R, Haemel A, et al. SJS-TEN Spectrum Reactions to Immune Checkpoint Inhibitor Therapy and Safety of Rechallenge: A Retrospective Review. *JAAD Case Reports*. Published online June 10, 2025. doi:10.1016/j.jdcr.2025.03.039

33. Qiu C, Shevchenko A, Hsu S. Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis. *JAAD Case Rep*. 2020;6(5):400-402. doi:10.1016/j.jdcr.2020.03.003